Selective dopamine D3
receptor antagonist (pKi
values are 8.0, 6.0, 5.0 and <5.2 for D3
respectively). Brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from GlaxoSmithKline.
Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A.
Reavill et al.
Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and
Stemp et al.
The citations listed below are publications that use Tocris products. Selected citations for SB 277011A dihydrochloride include:
Showing Results 1 - 1 of 1